Crescentic glomerulonephritis in children

Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included:...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric nephrology (Berlin, West) West), 1992-05, Vol.6 (3), p.231-235
Hauptverfasser: JARDIM, H. M. P. F, RISDON, R. A, BARRATT, T. M, DILLON, M. J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 235
container_issue 3
container_start_page 231
container_title Pediatric nephrology (Berlin, West)
container_volume 6
creator JARDIM, H. M. P. F
RISDON, R. A
BARRATT, T. M
DILLON, M. J
description Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05).
doi_str_mv 10.1007/BF00878354
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00878354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1352123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</originalsourceid><addsrcrecordid>eNpFzzFPwzAUBGALgUooLOxIGVhACrznF9f2SCsKSJVYOnSLbMehRmka2e3AvyeoFZ1uuE8nHWO3CE8IIJ-ncwAlFYnyjGVYEi9Qq9U5y0ATFlDi6pJdpfQNAxNqMmIjJMGRU8YeZtEn57tdcPlXu934uG-3ne_XMexCykOXu3Vo6-i7a3bRmDb5m2OO2XL-upy9F4vPt4_Zy6JwhLgrFNVa2JJLgsbyUivJrSVPkyHQarLUaNS100BGGosg_GA5cFLgEGnMHg-zLm5Tir6p-hg2Jv5UCNXf2-r0dsB3B9zv7cbXJ3q4N_T3x94kZ9omms6F9M-EkBMgSb9291oO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Crescentic glomerulonephritis in children</title><source>MEDLINE</source><source>Springer Journals</source><creator>JARDIM, H. M. P. F ; RISDON, R. A ; BARRATT, T. M ; DILLON, M. J</creator><creatorcontrib>JARDIM, H. M. P. F ; RISDON, R. A ; BARRATT, T. M ; DILLON, M. J</creatorcontrib><description>Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05).</description><identifier>ISSN: 0931-041X</identifier><identifier>EISSN: 1432-198X</identifier><identifier>DOI: 10.1007/BF00878354</identifier><identifier>PMID: 1352123</identifier><identifier>CODEN: PENED3</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Adrenal Cortex Hormones - therapeutic use ; Anticoagulants - therapeutic use ; Azathioprine - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; Cyclophosphamide - therapeutic use ; Female ; Glomerular Filtration Rate - physiology ; Glomerulonephritis ; Glomerulonephritis - complications ; Glomerulonephritis - drug therapy ; Glomerulonephritis - pathology ; Glomerulonephritis, Membranoproliferative - complications ; Glomerulonephritis, Membranoproliferative - drug therapy ; Glomerulonephritis, Membranoproliferative - pathology ; Granulomatosis with Polyangiitis - complications ; Granulomatosis with Polyangiitis - pathology ; Granulomatosis with Polyangiitis - physiopathology ; Hematuria - etiology ; Hematuria - physiopathology ; Humans ; Hypertension - etiology ; Hypertension - physiopathology ; Kidney - drug effects ; Kidney - pathology ; Kidney - physiopathology ; London ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - pathology ; Lupus Erythematosus, Systemic - physiopathology ; Male ; Medical sciences ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Polyarteritis Nodosa - complications ; Polyarteritis Nodosa - pathology ; Polyarteritis Nodosa - physiopathology ; Prognosis ; Purpura, Schoenlein-Henoch - complications ; Purpura, Schoenlein-Henoch - drug therapy ; Purpura, Schoenlein-Henoch - pathology ; Vasculitis - complications ; Vasculitis - drug therapy ; Vasculitis - pathology</subject><ispartof>Pediatric nephrology (Berlin, West), 1992-05, Vol.6 (3), p.231-235</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</citedby><cites>FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5576037$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1352123$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JARDIM, H. M. P. F</creatorcontrib><creatorcontrib>RISDON, R. A</creatorcontrib><creatorcontrib>BARRATT, T. M</creatorcontrib><creatorcontrib>DILLON, M. J</creatorcontrib><title>Crescentic glomerulonephritis in children</title><title>Pediatric nephrology (Berlin, West)</title><addtitle>Pediatr Nephrol</addtitle><description>Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05).</description><subject>Adolescent</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Anticoagulants - therapeutic use</subject><subject>Azathioprine - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Glomerular Filtration Rate - physiology</subject><subject>Glomerulonephritis</subject><subject>Glomerulonephritis - complications</subject><subject>Glomerulonephritis - drug therapy</subject><subject>Glomerulonephritis - pathology</subject><subject>Glomerulonephritis, Membranoproliferative - complications</subject><subject>Glomerulonephritis, Membranoproliferative - drug therapy</subject><subject>Glomerulonephritis, Membranoproliferative - pathology</subject><subject>Granulomatosis with Polyangiitis - complications</subject><subject>Granulomatosis with Polyangiitis - pathology</subject><subject>Granulomatosis with Polyangiitis - physiopathology</subject><subject>Hematuria - etiology</subject><subject>Hematuria - physiopathology</subject><subject>Humans</subject><subject>Hypertension - etiology</subject><subject>Hypertension - physiopathology</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Kidney - physiopathology</subject><subject>London</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Lupus Erythematosus, Systemic - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Polyarteritis Nodosa - complications</subject><subject>Polyarteritis Nodosa - pathology</subject><subject>Polyarteritis Nodosa - physiopathology</subject><subject>Prognosis</subject><subject>Purpura, Schoenlein-Henoch - complications</subject><subject>Purpura, Schoenlein-Henoch - drug therapy</subject><subject>Purpura, Schoenlein-Henoch - pathology</subject><subject>Vasculitis - complications</subject><subject>Vasculitis - drug therapy</subject><subject>Vasculitis - pathology</subject><issn>0931-041X</issn><issn>1432-198X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFzzFPwzAUBGALgUooLOxIGVhACrznF9f2SCsKSJVYOnSLbMehRmka2e3AvyeoFZ1uuE8nHWO3CE8IIJ-ncwAlFYnyjGVYEi9Qq9U5y0ATFlDi6pJdpfQNAxNqMmIjJMGRU8YeZtEn57tdcPlXu934uG-3ne_XMexCykOXu3Vo6-i7a3bRmDb5m2OO2XL-upy9F4vPt4_Zy6JwhLgrFNVa2JJLgsbyUivJrSVPkyHQarLUaNS100BGGosg_GA5cFLgEGnMHg-zLm5Tir6p-hg2Jv5UCNXf2-r0dsB3B9zv7cbXJ3q4N_T3x94kZ9omms6F9M-EkBMgSb9291oO</recordid><startdate>19920501</startdate><enddate>19920501</enddate><creator>JARDIM, H. M. P. F</creator><creator>RISDON, R. A</creator><creator>BARRATT, T. M</creator><creator>DILLON, M. J</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920501</creationdate><title>Crescentic glomerulonephritis in children</title><author>JARDIM, H. M. P. F ; RISDON, R. A ; BARRATT, T. M ; DILLON, M. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-83d95b42730fb249872bb3e362bb1b93b3f919dc903a7ab105e273202380c113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Anticoagulants - therapeutic use</topic><topic>Azathioprine - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Glomerular Filtration Rate - physiology</topic><topic>Glomerulonephritis</topic><topic>Glomerulonephritis - complications</topic><topic>Glomerulonephritis - drug therapy</topic><topic>Glomerulonephritis - pathology</topic><topic>Glomerulonephritis, Membranoproliferative - complications</topic><topic>Glomerulonephritis, Membranoproliferative - drug therapy</topic><topic>Glomerulonephritis, Membranoproliferative - pathology</topic><topic>Granulomatosis with Polyangiitis - complications</topic><topic>Granulomatosis with Polyangiitis - pathology</topic><topic>Granulomatosis with Polyangiitis - physiopathology</topic><topic>Hematuria - etiology</topic><topic>Hematuria - physiopathology</topic><topic>Humans</topic><topic>Hypertension - etiology</topic><topic>Hypertension - physiopathology</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Kidney - physiopathology</topic><topic>London</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Lupus Erythematosus, Systemic - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Polyarteritis Nodosa - complications</topic><topic>Polyarteritis Nodosa - pathology</topic><topic>Polyarteritis Nodosa - physiopathology</topic><topic>Prognosis</topic><topic>Purpura, Schoenlein-Henoch - complications</topic><topic>Purpura, Schoenlein-Henoch - drug therapy</topic><topic>Purpura, Schoenlein-Henoch - pathology</topic><topic>Vasculitis - complications</topic><topic>Vasculitis - drug therapy</topic><topic>Vasculitis - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JARDIM, H. M. P. F</creatorcontrib><creatorcontrib>RISDON, R. A</creatorcontrib><creatorcontrib>BARRATT, T. M</creatorcontrib><creatorcontrib>DILLON, M. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pediatric nephrology (Berlin, West)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JARDIM, H. M. P. F</au><au>RISDON, R. A</au><au>BARRATT, T. M</au><au>DILLON, M. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crescentic glomerulonephritis in children</atitle><jtitle>Pediatric nephrology (Berlin, West)</jtitle><addtitle>Pediatr Nephrol</addtitle><date>1992-05-01</date><risdate>1992</risdate><volume>6</volume><issue>3</issue><spage>231</spage><epage>235</epage><pages>231-235</pages><issn>0931-041X</issn><eissn>1432-198X</eissn><coden>PENED3</coden><abstract>Data on patients with crescentic glomerulonephritis (greater than 50% glomeruli with crescents), referred to the Hospital for Sick Children during the past 13 years, were reviewed. Thirty patients (13 male, 17 female) aged 3.7-15.7 years (mean 9.5) were evaluated. Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30). Henoch-Schönlein purpura was present in 9 patients, microscopic polyarteritis in 3, polyarteritis nodosa in 1, Wegener's granulomatosis in 1, systemic lupus erythematosus in 1, post-streptococcal glomerulonephritis in 2, mesangiocapillary glomerulonephritis in 7, anti-glomerular basement membrane glomerulonephritis in 2, and 4 were idiopathic. In 10 patients 50%-79% of glomeruli were affected by crescentic changes (group 1) and in the remaining 20, 80% or more (group 2). The crescents were cellular, fibrocellular or fibrous, and the degree of sclerosis was assessed. Patients in both groups were treated with plasma exchange, corticosteroids, anticoagulants, cyclophosphamide and azathioprine in different combinations. On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2. In our experience, 50% progressed to end-stage renal failure. The interval between disease onset and start of treatment was a prognostic factor for outcome. Fibrous crescents were associated with a worse outcome than fibrocellular crescents (P less than 0.05). Outcome was not, however, related to the percentage of glomeruli affected (P greater than 0.05).</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>1352123</pmid><doi>10.1007/BF00878354</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0931-041X
ispartof Pediatric nephrology (Berlin, West), 1992-05, Vol.6 (3), p.231-235
issn 0931-041X
1432-198X
language eng
recordid cdi_crossref_primary_10_1007_BF00878354
source MEDLINE; Springer Journals
subjects Adolescent
Adrenal Cortex Hormones - therapeutic use
Anticoagulants - therapeutic use
Azathioprine - therapeutic use
Biological and medical sciences
Child
Child, Preschool
Cyclophosphamide - therapeutic use
Female
Glomerular Filtration Rate - physiology
Glomerulonephritis
Glomerulonephritis - complications
Glomerulonephritis - drug therapy
Glomerulonephritis - pathology
Glomerulonephritis, Membranoproliferative - complications
Glomerulonephritis, Membranoproliferative - drug therapy
Glomerulonephritis, Membranoproliferative - pathology
Granulomatosis with Polyangiitis - complications
Granulomatosis with Polyangiitis - pathology
Granulomatosis with Polyangiitis - physiopathology
Hematuria - etiology
Hematuria - physiopathology
Humans
Hypertension - etiology
Hypertension - physiopathology
Kidney - drug effects
Kidney - pathology
Kidney - physiopathology
London
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - pathology
Lupus Erythematosus, Systemic - physiopathology
Male
Medical sciences
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Polyarteritis Nodosa - complications
Polyarteritis Nodosa - pathology
Polyarteritis Nodosa - physiopathology
Prognosis
Purpura, Schoenlein-Henoch - complications
Purpura, Schoenlein-Henoch - drug therapy
Purpura, Schoenlein-Henoch - pathology
Vasculitis - complications
Vasculitis - drug therapy
Vasculitis - pathology
title Crescentic glomerulonephritis in children
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T20%3A12%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crescentic%20glomerulonephritis%20in%20children&rft.jtitle=Pediatric%20nephrology%20(Berlin,%20West)&rft.au=JARDIM,%20H.%20M.%20P.%20F&rft.date=1992-05-01&rft.volume=6&rft.issue=3&rft.spage=231&rft.epage=235&rft.pages=231-235&rft.issn=0931-041X&rft.eissn=1432-198X&rft.coden=PENED3&rft_id=info:doi/10.1007/BF00878354&rft_dat=%3Cpubmed_cross%3E1352123%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1352123&rfr_iscdi=true